HER2在乳腺癌中不同表达状态及治疗药物研究进展

Advances in research on different status of HER2 in breast cancer and its drugs

乳腺癌(breast cancer)是严重威胁女性生命健康的第1大恶性肿瘤。以HER2为靶向的治疗经历20多年的发展,是影响乳腺癌患者预后和治疗策略的重要生物标志物。目前国内外指南推荐使用IHC与ISH相结合的方法检测HER2表达状态,并有共识在阴性患者中区分出HER2低表达。市场上治疗乳腺癌的药物包括抗体药物、小分子药物及ADC,可以针对HER2不同表达状态进行较为有效的治疗。该文针对HER2在乳腺癌中不同表达状态及治疗药物研究进展进行综述。

Breast cancer is the first malignant tumor,which seriously threatens women's life and health.HER2-targeted therapies have experienced more than 20 years of development and are important biomarkers affecting the prognosis and treatment strategies of breast cancer.Current guidelines use the combined detection method IHC and ISH to detect HER2 expressions,status in breast cancer.There is a consensus that classifying the HER2-low in negative patients.Anti-HER2 drugs on the market include antibodies,small-molecule drugs and ADCs,which can be used for effective treatment of different expression of HER2.This article reviewed the different expression status of HER2 in breast cancer and the research progress of anti-HER2 drugs.